Medicago announces two presentations at the 2008 AAPS National Biotechnology Conference

    QUEBEC CITY, June 23 /CNW/ - Medicago Inc. (TSX-V:MDG) (the "Company"),
today announced that it will be presenting an overview of its development of
vaccines generated from plant-made Virus-Like Particles and unique technology
platform at the 2008 American Association of Pharmaceutical Scientists (AAPS)
National Biotechnology Conference, from June 22-25, 2008, at the Metro
Convention Centre in Toronto, Ontario. Dr. Louis Vezina, Medicago's Chief
Scientific Officer will give a presentation on "How to Produce Therapeutic
Vaccines in Plants" in a Plenary Session entitled "Pharmaceutical
Biotechnology - the Next Steps", today at 8:30 am EDT. Ms. Irene Clement,
Acting Vice President Regulatory Affairs will give a presentation on
"Production and Characterization of Plant-based Vaccines and Therapeutic
Antibodies" in a Session entitled "Plant-based Biologicals: Developmental and
Regulatory Aspects" today at 1:00 pm EDT.

    About Medicago

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at

    Forward-Looking Statements

    This press release contains forward-looking statements which reflect
Medicago's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. Medicago disclaims any obligation to
update these forward-looking statements.

    The TSX Venture Exchange assumes no responsibility for the content or
    accuracy of this press release

    %SEDAR: 00023641E

For further information:

For further information: Medicago, Inc., Andy Sheldon, President and
CEO, (418) 658-9393; Investor relations: The Equicom Group Inc., Arianna
Vanin, (514) 844-4680,

Organization Profile

Medicago Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890